Novartis (NVS) Pauses Autoimmune CAR-T Trials After Three Deaths

Novartis (NVS) has paused its autoimmune CAR-T therapy trials following the deaths of three patients. This suspension raises safety concerns about the therapy's viability and effectiveness. The move aligns with Bristol Myers Squibb also halting its CAR-T studies due to similar issues. These developments may impact market confidence in both companies' future immunotherapy investments and overall market dynamics in the biotech sector.